US4235871A
(en)
|
1978-02-24 |
1980-11-25 |
Papahadjopoulos Demetrios P |
Method of encapsulating biologically active materials in lipid vesicles
|
US4501728A
(en)
|
1983-01-06 |
1985-02-26 |
Technology Unlimited, Inc. |
Masking of liposomes from RES recognition
|
US5019369A
(en)
|
1984-10-22 |
1991-05-28 |
Vestar, Inc. |
Method of targeting tumors in humans
|
US4837028A
(en)
|
1986-12-24 |
1989-06-06 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
US4920016A
(en)
|
1986-12-24 |
1990-04-24 |
Linear Technology, Inc. |
Liposomes with enhanced circulation time
|
JP3771253B2
(ja)
|
1988-09-02 |
2006-04-26 |
ダイアックス コープ. |
新規な結合タンパク質の生成と選択
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
ES2139598T3
(es)
|
1990-07-10 |
2000-02-16 |
Medical Res Council |
Procedimientos para la produccion de miembros de parejas de union especifica.
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
US5789650A
(en)
|
1990-08-29 |
1998-08-04 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
ES2108048T3
(es)
|
1990-08-29 |
1997-12-16 |
Genpharm Int |
Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
US5874299A
(en)
|
1990-08-29 |
1999-02-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5877397A
(en)
|
1990-08-29 |
1999-03-02 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
US5814318A
(en)
|
1990-08-29 |
1998-09-29 |
Genpharm International Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
DE69129154T2
(de)
|
1990-12-03 |
1998-08-20 |
Genentech Inc |
Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
|
EP1820858B1
(en)
|
1991-03-01 |
2009-08-12 |
Dyax Corporation |
Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
|
AU662148B2
(en)
|
1991-04-10 |
1995-08-24 |
Scripps Research Institute, The |
Heterodimeric receptor libraries using phagemids
|
DE69230142T2
(de)
|
1991-05-15 |
2000-03-09 |
Cambridge Antibody Tech |
Verfahren zur herstellung von spezifischen bindungspaargliedern
|
DE4122599C2
(de)
|
1991-07-08 |
1993-11-11 |
Deutsches Krebsforsch |
Phagemid zum Screenen von Antikörpern
|
ES2136092T3
(es)
|
1991-09-23 |
1999-11-16 |
Medical Res Council |
Procedimientos para la produccion de anticuerpos humanizados.
|
US6214334B1
(en)
|
1991-10-21 |
2001-04-10 |
Trustees Of The University Of Pennsylvania |
Compositions and methods for producing and using homogenous neuronal cell transplants to treat neurodegenerative disorders and brain and spinal cord injuries
|
US5681747A
(en)
|
1992-03-16 |
1997-10-28 |
Isis Pharmaceuticals, Inc. |
Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof
|
US5733743A
(en)
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
AU687010B2
(en)
|
1992-07-17 |
1998-02-19 |
Dana-Farber Cancer Institute |
Method of intracellular binding of target molecules
|
DE4239877C1
(de)
|
1992-11-27 |
1994-03-17 |
Boehringer Ingelheim Int |
Stabilisierte Superoxid-Dismutase (SOD)-Zusammensetzung
|
WO1995003832A1
(en)
|
1993-07-30 |
1995-02-09 |
Thomas Jefferson University |
Intracellular immunization
|
FR2721943B1
(fr)
|
1994-06-29 |
1996-08-02 |
Rhone Poulenc Rorer Sa |
Adenovirus comprenant un gene codant pour une superoxyde dismutase
|
US5556837A
(en)
|
1994-08-01 |
1996-09-17 |
Regeneron Pharmaceuticals Inc. |
Methods for treating addictive disorders
|
US5614649A
(en)
|
1994-11-14 |
1997-03-25 |
Cephalon, Inc. |
Multicatalytic protease inhibitors
|
US5783683A
(en)
|
1995-01-10 |
1998-07-21 |
Genta Inc. |
Antisense oligonucleotides which reduce expression of the FGFRI gene
|
US5853987A
(en)
|
1995-04-24 |
1998-12-29 |
The Texas A & M University System |
Decorin binding protein compositions and methods of use
|
US5834457A
(en)
|
1996-01-26 |
1998-11-10 |
The Regents Of The University Of California |
Method of modulating radical formation by mutant cuznsod enzymes
|
JP4427106B2
(ja)
|
1997-03-18 |
2010-03-03 |
オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド |
平滑筋腫を治療および診断するための方法およびキット
|
US7863444B2
(en)
|
1997-03-19 |
2011-01-04 |
Abbott Laboratories |
4-aminopyrrolopyrimidines as kinase inhibitors
|
US6723694B1
(en)
|
1997-05-21 |
2004-04-20 |
The Children's Medical Center Corp. |
Short peptides which selectively modulate intracellular signalling
|
GB9718913D0
(en)
|
1997-09-05 |
1997-11-12 |
Glaxo Group Ltd |
Substituted oxindole derivatives
|
US6096778A
(en)
|
1997-10-07 |
2000-08-01 |
Cephalon, Inc. |
α-ketoamide multicatalytic protease inhibitors
|
US20010006793A1
(en)
|
1998-03-20 |
2001-07-05 |
Mary-Ann Bjornsti |
Modulators of eukaryotic caspases
|
ZA200007412B
(en)
|
1998-05-15 |
2002-03-12 |
Imclone Systems Inc |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
|
WO1999065509A1
(en)
|
1998-06-15 |
1999-12-23 |
Neuronz Limited |
Regulation of tyrosine hydroxylase
|
US6713474B2
(en)
|
1998-09-18 |
2004-03-30 |
Abbott Gmbh & Co. Kg |
Pyrrolopyrimidines as therapeutic agents
|
US6927044B2
(en)
|
1998-09-25 |
2005-08-09 |
Regeneron Pharmaceuticals, Inc. |
IL-1 receptor based cytokine traps
|
US6319905B1
(en)
|
1998-12-29 |
2001-11-20 |
Cell Genesys, Inc. |
Method of controlling L-Dopa production and of treating dopamine deficiency
|
US6841567B1
(en)
|
1999-02-12 |
2005-01-11 |
Cephalon, Inc. |
Cyclic substituted fused pyrrolocarbazoles and isoindolones
|
US6624171B1
(en)
|
1999-03-04 |
2003-09-23 |
Smithkline Beecham Corporation |
Substituted aza-oxindole derivatives
|
US6312949B1
(en)
|
1999-03-26 |
2001-11-06 |
The Salk Institute For Biological Studies |
Regulation of tyrosine hydroxylase expression
|
US6297238B1
(en)
|
1999-04-06 |
2001-10-02 |
Basf Aktiengesellschaft |
Therapeutic agents
|
US6982265B1
(en)
|
1999-05-21 |
2006-01-03 |
Bristol Myers Squibb Company |
Pyrrolotriazine inhibitors of kinases
|
US20030125276A1
(en)
|
2001-11-08 |
2003-07-03 |
Isis Pharmaceuticals Inc. |
Antisense modulation of thyroid hormone receptor interactor 6 expression
|
US6921763B2
(en)
|
1999-09-17 |
2005-07-26 |
Abbott Laboratories |
Pyrazolopyrimidines as therapeutic agents
|
US6797720B2
(en)
|
1999-12-03 |
2004-09-28 |
Ono Pharmaceutical Co., Ltd. |
1,3,4-oxadiazoline derivative and an agent comprising its derivative as active ingredient
|
US7144901B2
(en)
|
1999-12-03 |
2006-12-05 |
Ono Pharmaceutical Co.,Ltd. |
Oxadiazole derivatives and drugs containing these derivatives as the active ingredient
|
US6334998B1
(en)
|
1999-12-07 |
2002-01-01 |
Parker Hughes Institute |
Estrogens for treating ALS
|
ES2245955T3
(es)
|
1999-12-21 |
2006-02-01 |
Sugen, Inc. |
7-aza-indolin-2-onas 4-sustituidas y su utilizacion como inhibidores de proteina-quinasa.
|
US7108984B2
(en)
|
2000-01-12 |
2006-09-19 |
Mount Sinai School Of Medicine |
Methods of identifying modulators of the FGF receptor
|
US20020081663A1
(en)
|
2000-01-05 |
2002-06-27 |
Conklin Darrell C. |
Novel FGF homolog ZFGF11
|
AU2001228810A1
(en)
|
2000-01-26 |
2001-08-07 |
Ono Pharmaceutical Co. Ltd. |
Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient
|
JP2001292778A
(ja)
|
2000-04-11 |
2001-10-23 |
Inst Of Physical & Chemical Res |
トランケート型リーリンタンパク質およびそれをコードするdna
|
US6372250B1
(en)
|
2000-04-25 |
2002-04-16 |
The Regents Of The University Of California |
Non-invasive gene targeting to the brain
|
US20030211967A1
(en)
|
2001-05-07 |
2003-11-13 |
Bryant Henry Uhlman |
Method for selectively inhibiting ghrelin action
|
WO2001092292A2
(en)
|
2000-05-30 |
2001-12-06 |
Merck & Co., Inc. |
Ghrelin analogs
|
WO2002000853A2
(en)
|
2000-06-26 |
2002-01-03 |
Bayer Aktiengesellschaft |
Regulation of human caspase-1-like protease
|
JP2002017361A
(ja)
|
2000-07-04 |
2002-01-22 |
Inst Of Physical & Chemical Res |
リーリンタンパク質cr−50エピトープ領域
|
JP4409135B2
(ja)
*
|
2000-12-01 |
2010-02-03 |
武田薬品工業株式会社 |
生理活性物質含有製剤の製造法
|
US7381701B2
(en)
|
2001-02-15 |
2008-06-03 |
The Borad Of Trustees Of The University Of Illinois |
Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
|
US20040116669A1
(en)
|
2001-03-23 |
2004-06-17 |
Hisao Tajima |
Prostaglandin ep1 receptor
|
WO2002083131A1
(en)
|
2001-04-13 |
2002-10-24 |
The Regents Of The University Of California |
Activators and ligands of ppar-beta/delta for the treatment of skin conditions
|
WO2002085308A2
(en)
|
2001-04-24 |
2002-10-31 |
Epigenesis Pharmaceuticals, Inc. |
Antisense and anti-inflammatory based compositions to treat respiratory disorders
|
US20050182006A1
(en)
|
2001-05-18 |
2005-08-18 |
Sirna Therapeutics, Inc |
RNA interference mediated inhibition of protein kinase C alpha (PKC-alpha) gene expression using short interfering nucleic acid (siNA)
|
WO2002096892A1
(fr)
|
2001-05-31 |
2002-12-05 |
Ono Pharmaceutical Co., Ltd. |
Composes derives d'oxadiazole et medicaments contenant ces composes comme ingredient actif
|
US7736677B2
(en)
|
2001-06-20 |
2010-06-15 |
Metaproteomics, Llc |
Xanthohumol and tetrahydro-isoalpha acid based protein kinase modulation cancer treatment
|
EP2221376B1
(en)
|
2001-06-21 |
2012-11-21 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of superoxide dismutase 1, soluble expression
|
US20040247592A1
(en)
|
2001-07-03 |
2004-12-09 |
Roifman Chaim M. |
Ephrin and eph receptor mediated immune modulation
|
DE10134196B4
(de)
|
2001-07-13 |
2005-08-18 |
Forschungszentrum Karlsruhe Gmbh Technik Und Umwelt |
Pharmazeutische Zusammensetzung zur Hemmung der unkontrollierten Vermehrung und/oder Induzierung der Apoptose von Zellen
|
US7348140B1
(en)
|
2001-07-25 |
2008-03-25 |
Acadia Pharmaceuticals, Inc. |
Clinical indications for genotyping polymorphic variants of G-protein coupled receptors
|
WO2003015615A2
(en)
|
2001-08-15 |
2003-02-27 |
Brown University Research Foundation |
Treatment of muscular dystrophies and related disorders
|
WO2003016343A2
(en)
|
2001-08-16 |
2003-02-27 |
Angiogene Inc. |
USE OF αCP1, αCP2, AND HUR FOR MODULATING GENE EXPRESSION AND INDUCING ANGIOGENESIS
|
CN1575184A
(zh)
|
2001-09-07 |
2005-02-02 |
波士顿大学理事会 |
治疗免疫复合物相关疾病的方法和组合物
|
BR0213097A
(pt)
|
2001-10-05 |
2005-02-01 |
Coley Pharm Gmbh |
Agonistas e antagonistas sinalizadores do receptor 3 similar a toll
|
US20030078199A1
(en)
|
2001-10-09 |
2003-04-24 |
Youmin Shu |
Human EphA6 gene and polypeptide
|
DE60232739D1
(de)
|
2001-10-12 |
2009-08-06 |
Nippon Chemiphar Co |
Aktivator des peroxisomproliferator-aktivierten rezeptors delta
|
CA2463492A1
(en)
|
2001-10-18 |
2003-04-24 |
Genentech, Inc. |
Methods for the treatment of carcinoma
|
CA2464887A1
(en)
|
2001-10-30 |
2003-05-08 |
Biogen, Inc. |
Methods and compositions for treating parkinson's disease
|
PL369738A1
(en)
|
2001-11-05 |
2005-05-02 |
Merck Patent Gmbh |
Hydrazono-malonitriles
|
US20030165485A1
(en)
|
2001-11-09 |
2003-09-04 |
Goran Bertilsson |
Functional role and potential therapeutic use of Reelin, Gas6 and Protein S in relation to adult neural stem or progenitor cells
|
AU2002365887A1
(en)
|
2001-11-29 |
2003-06-17 |
U.S. Department Of Veterans Affairs |
Use of gingko biloba extracts to promote neuroprotection and reduce weight loss
|
CA2468083C
(en)
|
2001-12-06 |
2016-02-23 |
Fibrogen, Inc. |
Use of heterocyclic carboxamides to treat anemia
|
WO2003051387A1
(fr)
|
2001-12-19 |
2003-06-26 |
Itoham Foods Inc. |
Agents therapeutiques et/ou prophylactiques contre des maladies conformationnelles
|
JP2005530687A
(ja)
|
2002-01-31 |
2005-10-13 |
マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ |
Fgfrアゴニスト
|
US20030225098A1
(en)
|
2002-03-21 |
2003-12-04 |
Hirst Gavin C. |
Kinase inhibitors
|
US20030199525A1
(en)
|
2002-03-21 |
2003-10-23 |
Hirst Gavin C. |
Kinase inhibitors
|
KR20050004809A
(ko)
|
2002-03-22 |
2005-01-12 |
어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. |
말초 맥관 질환 치료 및/또는 예방에 사용되는 il-18저해제
|
US20050164298A1
(en)
|
2002-03-26 |
2005-07-28 |
Stefan Golz |
Diagnostics and therapeutics for diseases associated with growth hormone secretagogue receptor(ghs)
|
IL149562A0
(en)
|
2002-05-09 |
2002-11-10 |
Prochon Ltd |
Fgf variants and methods for use thereof
|
JP5000848B2
(ja)
|
2002-05-21 |
2012-08-15 |
第一三共株式会社 |
グレリン含有医薬組成物
|
US7115654B2
(en)
|
2002-06-05 |
2006-10-03 |
Sunesis Pharmaceuticals, Inc. |
Caspase-1 inhibitors and methods for their use
|
US20040022765A1
(en)
|
2002-07-31 |
2004-02-05 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Ran GTPase activating protein 1 expression
|
MXPA05000160A
(es)
|
2002-07-05 |
2006-02-28 |
Chugai Pharmaceutical Co Ltd |
Producto terapeutico para la diabetes mellitus.
|
TWI329112B
(en)
|
2002-07-19 |
2010-08-21 |
Bristol Myers Squibb Co |
Novel inhibitors of kinases
|
AU2003251681A1
(en)
|
2002-08-01 |
2004-02-23 |
Noxxon Pharma Ag |
Ghrelin binding nucleic acids
|
EP1543009A4
(en)
|
2002-08-02 |
2007-08-08 |
Bristol Myers Squibb Co |
Pyrrolotriazine KINASE INHIBITORS
|
DE10244453A1
(de)
|
2002-09-24 |
2004-04-01 |
Phenomiques Gmbh |
Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
|
EP1407760A1
(de)
|
2002-10-08 |
2004-04-14 |
Cognis France S.A. |
Verfahren zum Schutz der Haut gegen Alterung
|
EP1558640B1
(en)
|
2002-10-29 |
2011-04-13 |
Anaphore, Inc. |
Trimeric binding proteins for trimeric cytokines
|
WO2004042027A2
(en)
|
2002-11-04 |
2004-05-21 |
University Of Massachusetts |
Allele-specific rna interference
|
EP2213738B1
(en)
|
2002-11-14 |
2012-10-10 |
Dharmacon, Inc. |
siRNA molecules targeting Bcl-2
|
JP3810731B2
(ja)
|
2002-11-29 |
2006-08-16 |
独立行政法人科学技術振興機構 |
哺乳動物のToll様受容体3に結合する新規アダプタータンパク質およびその遺伝子
|
US8124582B2
(en)
|
2002-12-06 |
2012-02-28 |
Fibrogen, Inc. |
Treatment of diabetes
|
DK1891966T3
(da)
|
2002-12-20 |
2012-04-02 |
Lundbeck & Co As H |
Modulation af neurotrophinaktivitet; fremgangsmåde til screening
|
CA2513584A1
(en)
|
2003-01-20 |
2004-08-05 |
Vib Vzw |
The use of yop proteins or rho gtpase inhibitors as caspase-1 inhibitors
|
US7354933B2
(en)
|
2003-01-31 |
2008-04-08 |
Aventis Pharma Sa |
Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
|
CN101444621B
(zh)
|
2003-02-11 |
2013-11-20 |
夏尔人类遗传性治疗公司 |
使用甲酰-甘氨酸生成酶(fge)对多种硫酸酯酶缺乏症和其它病症进行诊断和治疗
|
US20040220270A1
(en)
|
2003-03-07 |
2004-11-04 |
The Jackson Laboratory |
Methods and composition of treating glaucoma by modulating tyrosinase/L-DOPA pathway
|
US7652033B2
(en)
|
2003-03-27 |
2010-01-26 |
Emory University |
HIF-1 inhibitors
|
WO2004093812A2
(en)
|
2003-04-22 |
2004-11-04 |
Irm Llc |
Compounds that induce neuronal differentiation in embryonic stem cells
|
US20040242559A1
(en)
|
2003-04-25 |
2004-12-02 |
Aventis Pharma S.A. |
Novel indole derivatives, preparation thereof as medicinal products and pharmaceutical compositions, and especially as KDR inhibitors
|
US20050043233A1
(en)
|
2003-04-29 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
|
ES2383685T3
(es)
|
2003-04-30 |
2012-06-25 |
Kenji Kangawa |
Preventivos o remedios para hepatopatía
|
WO2004098520A2
(en)
|
2003-05-01 |
2004-11-18 |
Irm Llc |
Compounds and compositions as protein kinase inhibitors
|
EP1636228B1
(de)
|
2003-05-23 |
2008-10-22 |
AEterna Zentaris GmbH |
Neue pyridopyrazine und deren verwendung als modulatoren von kinasen
|
US7476653B2
(en)
|
2003-06-18 |
2009-01-13 |
Tranzyme Pharma, Inc. |
Macrocyclic modulators of the ghrelin receptor
|
EP1633866A1
(en)
|
2003-06-18 |
2006-03-15 |
Direvo Biotech AG |
New biological entities and the pharmaceutical or diagnostic use thereof
|
WO2005007672A2
(en)
|
2003-06-20 |
2005-01-27 |
Coley Pharmaceutical Gmbh |
Small molecule toll-like receptor (tlr) antagonists
|
US8592391B2
(en)
|
2003-07-01 |
2013-11-26 |
Andres Salazar |
Method for therapeutic, clinical and veterinary use poly-ICLC
|
EP1644335A4
(en)
|
2003-07-11 |
2008-06-04 |
Bristol Myers Squibb Co |
TETRAHYDROQUINOLINE DERIVATIVES COMPRISING MODULATORS OF CANNABINOID RECEPTORS
|
US20090105149A1
(en)
|
2003-08-07 |
2009-04-23 |
Enkam Pharmaceuticals A/S |
Compounds comprising lpa
|
SI1680140T1
(sl)
|
2003-10-16 |
2011-08-31 |
Imclone Llc |
Inhibitorji receptorja-1 za fibroblastni rastni faktor in metode za zdravljenje z le-temi
|
WO2005040792A2
(en)
|
2003-10-21 |
2005-05-06 |
Bayer Healthcare Ag |
Diagnostics and therapeutics for diseases associated with arginyl aminopeptidase (aminopeptidase b)-like 1 (rnpepl1)
|
GB0325031D0
(en)
|
2003-10-27 |
2003-12-03 |
Novartis Ag |
Organic compounds
|
CA2544602A1
(en)
|
2003-11-04 |
2005-05-26 |
Elixir Pharmaceuticals, Inc. |
Therapeutic compounds and uses thereof
|
EP1696877A4
(en)
|
2003-11-13 |
2010-06-09 |
Gen Hospital Corp |
PROCESS FOR PAIN TREATMENT
|
WO2005048916A2
(en)
|
2003-11-20 |
2005-06-02 |
Biovitrum Ab |
Tetrahydrospiro-beta-carboline-1,3 '-pyrrolidine derivatives and their use in ghsr-related disorders
|
JPWO2005051425A1
(ja)
|
2003-11-26 |
2008-04-24 |
第一製薬株式会社 |
プロカスパーゼ1活性化阻害剤
|
EP1699477A2
(en)
|
2003-12-11 |
2006-09-13 |
Theravance, Inc. |
Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
|
EP1697420A2
(en)
|
2003-12-19 |
2006-09-06 |
Five Prime Therapeutics, Inc. |
Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
|
DK1697370T3
(da)
|
2003-12-19 |
2007-09-17 |
Bristol Myers Squibb Co |
Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
|
EP1704228B1
(en)
|
2004-01-16 |
2012-04-11 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Immunokinases
|
US20050222171A1
(en)
|
2004-01-22 |
2005-10-06 |
Guido Bold |
Organic compounds
|
US20070281986A1
(en)
|
2004-02-03 |
2007-12-06 |
Collier Gregory R |
Methods and Compositions for Modulating Satiety
|
EP1720567A2
(en)
|
2004-02-10 |
2006-11-15 |
Innate Pharma |
Composition and method for the treatment of carcinoma
|
WO2005079390A2
(en)
|
2004-02-13 |
2005-09-01 |
Boston Biomedical Research Institute |
Inhibition of fgf signaling
|
WO2005085443A2
(en)
|
2004-03-01 |
2005-09-15 |
Massachusetts Institute Of Technology |
Rnai-based therapeutics for allergic rhinitis and asthma
|
US20060211752A1
(en)
|
2004-03-16 |
2006-09-21 |
Kohn Leonard D |
Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
|
EP1730520A2
(en)
|
2004-03-24 |
2006-12-13 |
Bayer HealthCare AG |
Diagnostics and therapeutics for diseases associated with peroxisome proliferator activated receptor delta (ppard)
|
FR2868422B1
(fr)
|
2004-03-31 |
2006-07-14 |
Aventis Pharma Sa |
Nouveaux derives pyrrolo(2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
|
BRPI0508180A
(pt)
|
2004-04-01 |
2007-08-07 |
Aventis Pharma Inc |
1,3,4-oxadiazol-2-onas como moduladores de ppar delta e seu uso deste
|
BRPI0509540A
(pt)
|
2004-04-01 |
2007-09-18 |
Aventis Pharma Inc |
uso de agonistas do receptor delta ativado pelo proliferador de peroxissoma para o tratamento de ms e outras doenças desmielinizantes
|
WO2005096781A2
(en)
|
2004-04-06 |
2005-10-20 |
University Of Massachusetts |
Methods and compositions for treating gain-of-function disorders using rna interference
|
JP4878551B2
(ja)
|
2004-04-08 |
2012-02-15 |
貞和 相磯 |
運動ニューロン疾患治療薬
|
US7838645B2
(en)
*
|
2004-04-30 |
2010-11-23 |
University Of Maryland College Park |
Function of autophagy genes in cell death
|
US7357933B2
(en)
|
2004-05-05 |
2008-04-15 |
Enhan Technology Holdings International Co., Ltd. |
Sporoderm-broken germination-activated ganoderma lucidum spores for protection of dopaminergic neurons and treatment of Parkinson's disease
|
WO2005113596A2
(en)
|
2004-05-14 |
2005-12-01 |
Receptor Biologix, Inc. |
Cell surface receptor isoforms and methods of identifying and using the same
|
MXPA06013256A
(es)
|
2004-05-15 |
2007-02-08 |
Vertex Pharma |
Tratamiento de crisis convulsivas utilizando inhibidores ice.
|
GB0411791D0
(en)
|
2004-05-26 |
2004-06-30 |
Cyclacel Ltd |
Compounds
|
EP1761539A1
(en)
|
2004-06-02 |
2007-03-14 |
Takeda Pharmaceutical Company Limited |
Indole derivative and use for treatment of cancer
|
US20060009452A1
(en)
|
2004-06-03 |
2006-01-12 |
Atamas Sergei P |
Therapeutic targeting of PARC/CCL18 and its signaling in pulmonary fibrosis
|
US7459426B2
(en)
|
2004-06-04 |
2008-12-02 |
Regeneron Pharmaceuticals, Inc. |
Methods of using IL-1 antagonists to treat autoinflammatory disease
|
US7102002B2
(en)
|
2004-06-16 |
2006-09-05 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
JP2008504236A
(ja)
|
2004-06-18 |
2008-02-14 |
エンカム ファーマシューティカルズ アクティーゼルスカブ |
Fgfr結合性ペプチド
|
KR20070043795A
(ko)
|
2004-07-20 |
2007-04-25 |
쉐링 코포레이션 |
톨-유사 수용체 발현 종양 세포에서 세포자멸사의 유도방법
|
EP1621536A1
(en)
|
2004-07-27 |
2006-02-01 |
Aventis Pharma S.A. |
Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
|
EP1621535A1
(en)
|
2004-07-27 |
2006-02-01 |
Aventis Pharma S.A. |
Substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
|
EP1621539A1
(en)
|
2004-07-27 |
2006-02-01 |
Aventis Pharma S.A. |
Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
|
CA2577060A1
(en)
|
2004-08-13 |
2006-02-23 |
Amgen Inc. |
Substituted benzofused heterocycles
|
AU2005277567A1
(en)
|
2004-08-16 |
2006-03-02 |
Medimmune, Llc |
Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity
|
WO2006027147A2
(en)
|
2004-09-09 |
2006-03-16 |
Bayer Healthcare Ag |
Diagnostics and therapeutics for diseases associated with adrenomedullin receptor (amdr)
|
WO2006030437A2
(en)
|
2004-09-17 |
2006-03-23 |
Biomas Ltd. |
Novel tellurium compounds and their use as immunomodulators
|
FR2876103B1
(fr)
|
2004-10-01 |
2008-02-22 |
Aventis Pharma Sa |
Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
|
WO2006047639A2
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune, Inc. |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
AU2005327921A1
(en)
|
2004-11-01 |
2006-08-31 |
University Of Southern California |
Novel compounds for treatment of cancer and disorders associated with angiogenesis function
|
WO2006054129A1
(en)
|
2004-11-19 |
2006-05-26 |
Institut Gustave Roussy |
Improved treatment of cancer by double-stranded rna
|
EP1662259A1
(en)
|
2004-11-25 |
2006-05-31 |
Cellzome Ag |
Use of Eph receptor inhibitors for the treatment of neurodegenerative diseases
|
EP1828243A2
(en)
|
2004-11-30 |
2007-09-05 |
Gastrotech Pharma A/S |
Growth hormone secretagogue receptor 1a ligands
|
AR051836A1
(es)
|
2004-11-30 |
2007-02-14 |
Centocor Inc |
Antagonistas de receptor 3 simil toll metodos y usos
|
US8399241B2
(en)
|
2004-12-01 |
2013-03-19 |
Whitehead Institute For Biomedical Research |
Modulators of alpha-synuclein toxicity
|
KR100967868B1
(ko)
|
2004-12-17 |
2010-07-05 |
베쓰 이스라엘 디코니스 메디칼 센터 |
박테리아 매개 유전자 침묵을 위한 조성물 및 이것을이용하는 방법
|
US7834064B2
(en)
|
2005-01-03 |
2010-11-16 |
Andres Mario Salazar |
Clinical method for the immunomodulatory and vaccine adjuvant use of poly-ICLC and other dsRNAs
|
JP2008526889A
(ja)
|
2005-01-10 |
2008-07-24 |
リサーチ ディベロップメント ファウンデーション |
癌治療のための標的化キメラ分子
|
US20060160737A1
(en)
|
2005-01-14 |
2006-07-20 |
Allen Radin |
Methods of using IL-1 antagonists to treat polymyalgia rheumatica and giant cell arteritis
|
US20060194821A1
(en)
|
2005-02-18 |
2006-08-31 |
The Brigham And Women's Hospital, Inc. |
Compounds inhibiting the aggregation of superoxide dismutase-1
|
US7560436B2
(en)
|
2005-02-22 |
2009-07-14 |
The Regents Of The University Of California |
Methods of treating gastrointestinal inflammation
|
WO2006094124A2
(en)
|
2005-03-02 |
2006-09-08 |
The Scripps Research Institute |
Compositions and methods for treatment of autoimmune and related diseases
|
US8158586B2
(en)
|
2005-04-11 |
2012-04-17 |
Pharmagap Inc. |
Inhibitors of protein kinases and uses thereof
|
WO2006122931A1
(en)
|
2005-05-20 |
2006-11-23 |
Biovitrum Ab (Publ) |
Beta-carboline derivatives and theri use as ghsr modulators
|
US20090074676A1
(en)
|
2005-05-23 |
2009-03-19 |
Smithkline Beecham Corporation |
Inhibition of p38 MAPK For Treatment Of Obesity
|
WO2006127976A2
(en)
|
2005-05-24 |
2006-11-30 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to ptpru
|
NZ565731A
(en)
|
2005-07-11 |
2011-10-28 |
Cbio Ltd |
Chaperonin 10-induced immunomodulation
|
GB0515026D0
(en)
|
2005-07-21 |
2005-08-31 |
Novartis Ag |
Organic compounds
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
US8759029B2
(en)
|
2005-08-31 |
2014-06-24 |
Universite Laval |
Antibodies and their use in the treatment, prevention and diagnosis of a disease associated with SOD1 abnormalities
|
US20090105138A1
(en)
|
2005-09-06 |
2009-04-23 |
Trinity Therapeutics, Inc. |
Methods for treating immune mediated neurological diseases
|
FR2891273B1
(fr)
|
2005-09-27 |
2007-11-23 |
Aventis Pharma Sa |
NOUVEAUX DERIVES BENZIMIDAZOLES ET BENZOTHIAZOLES, LEUR PREPARATION ET LEUR UTILISATION PHARMACEUTIQUE NOTAMMENT COMME INHIBITEURS DE CMet
|
CN105169369B
(zh)
|
2005-09-30 |
2019-10-18 |
中美华世通生物医药科技(武汉)有限公司 |
治疗和预防丙型肝炎感染的方法和药物组合物
|
US20070155820A1
(en)
|
2005-11-23 |
2007-07-05 |
Auspex Pharmaceuticals, Inc. |
Substituted aryloxypropylamines with serotoninergic and/or norepinephrinergic activity
|
CA2624179A1
(en)
|
2005-10-06 |
2007-04-12 |
Auspex Pharmaceuticals, Inc. |
Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
|
CN104278037B
(zh)
|
2005-10-12 |
2020-09-15 |
艾德拉药物股份有限公司 |
基于变异应答调制Toll样受体的免疫调节寡核苷酸(IRO)化合物
|
CN101330922A
(zh)
|
2005-10-20 |
2008-12-24 |
悉生物有限公司 |
超敏的治疗
|
WO2007048027A2
(en)
|
2005-10-21 |
2007-04-26 |
Novartis Ag |
Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
|
EP1945820B1
(en)
|
2005-10-27 |
2013-08-28 |
Janssen Biotech, Inc. |
Toll like receptor 3 modulators, methods and uses
|
EP1945657B1
(en)
|
2005-10-28 |
2011-10-26 |
Janssen Biotech, Inc. |
Tlr3 glycosylation site muteins and methods of use
|
AU2006315684A1
(en)
|
2005-11-14 |
2007-05-24 |
Auspex Pharmaceuticals, Inc. |
Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
|
WO2007064697A1
(en)
|
2005-12-01 |
2007-06-07 |
Auspex Pharmaceuticals, Inc. |
Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
|
US20070259827A1
(en)
|
2006-01-25 |
2007-11-08 |
University Of Massachusetts |
Compositions and methods for enhancing discriminatory RNA interference
|
JP2009524430A
(ja)
|
2006-01-26 |
2009-07-02 |
ユニバーシティ オブ マサチューセッツ |
治療的使用のためのrna干渉剤
|
KR101446499B1
(ko)
|
2006-01-27 |
2014-10-06 |
피브로겐, 인크. |
저산소증 유발가능 인자(hif)를 안정시키는 시아노이소퀴놀린 화합물
|
EP1987028A2
(en)
|
2006-02-10 |
2008-11-05 |
Transtech Pharma, Inc. |
Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
|
EP1986657A4
(en)
|
2006-02-16 |
2011-07-20 |
Discogen Llc |
METHOD OF TREATING A SUBJECT SUFFERING FROM DEGENERATIVE DISCOPATHY BY A MATRIX METALLOPROTEASE INHIBITOR
|
WO2007103048A2
(en)
|
2006-03-01 |
2007-09-13 |
Regents Of The University Of Colorado |
Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
|
US7674811B2
(en)
|
2006-03-14 |
2010-03-09 |
Ranbaxy Laboratories Limited |
5-lipoxygenase inhibitors
|
WO2007106792A2
(en)
*
|
2006-03-15 |
2007-09-20 |
Thorner Michael O |
Methods for treating sarcopenia with a growth hormone secretagogue
|
US20070232556A1
(en)
|
2006-03-31 |
2007-10-04 |
Montine Thomas J |
Methods and compositions for the treatment of neurological diseases and disorders
|
RU2461557C2
(ru)
|
2006-04-04 |
2012-09-20 |
Файброджен, Инк. |
Соединения пирроло- и тиазолопиридина (варианты) и фармацевтическая композиция на их основе
|
US20070249519A1
(en)
|
2006-04-20 |
2007-10-25 |
Kalypsys, Inc. |
Methods for the upregulation of glut4 via modulation of ppar delta in adipose tissue and for the treatment of disease
|
WO2007127457A2
(en)
|
2006-04-28 |
2007-11-08 |
The Administrators Of The Tulane Educational Fund |
Ghrelin/growth hormone releasing peptide/growth hormone secretatogue receptor antagonists and uses thereof
|
AU2007256893A1
(en)
|
2006-06-05 |
2007-12-13 |
Auspex Pharmaceuticals, Inc. |
Preparation and utility of substituted imidazopyridine compounds with hypnotic effects
|
CA2654450A1
(en)
|
2006-06-05 |
2007-12-13 |
Auspex Pharmaceuticals, Inc. |
Preparation and utility of substituted erythromycin analogs
|
US20070287734A1
(en)
|
2006-06-09 |
2007-12-13 |
Auspex Pharmaceuticals, Inc. |
Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity
|
WO2007146977A1
(en)
|
2006-06-15 |
2007-12-21 |
Boehringer Ingelheim International Gmbh |
2-anilino-4-aminoalkyleneaminopyrimidines
|
AU2007257650A1
(en)
|
2006-06-15 |
2007-12-21 |
Boehringer Ingelheim International Gmbh |
2-anilino-4-(heterocyclic)amino-pyrimidines as inhibitors of protein kinase C-alpha
|
JP2009541329A
(ja)
|
2006-06-20 |
2009-11-26 |
メタプロテオミクス, エルエルシー |
ヘキサヒドロ−イソアルファ酸に基づくタンパク質キナーゼ調節癌治療
|
US8088733B2
(en)
|
2006-07-06 |
2012-01-03 |
Tranzyme Pharma Inc. |
Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders
|
US7585865B2
(en)
|
2006-07-21 |
2009-09-08 |
The Penn State Research Foundation |
Protein kinase C zeta inhibition to treat vascular permeability
|
WO2008016677A2
(en)
|
2006-08-02 |
2008-02-07 |
Auspex Pharmaceuticals, Inc. |
Preparation and utility of deuterated amphetamines
|
CN101547696A
(zh)
|
2006-08-08 |
2009-09-30 |
奥斯拜客斯制药有限公司 |
具有α肾上腺素能阻断效应的取代喹唑啉化合物的制备和应用
|
US8063225B2
(en)
|
2006-08-14 |
2011-11-22 |
Chembridge Corporation |
Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
|
JP2010501011A
(ja)
|
2006-08-16 |
2010-01-14 |
オースペックス・ファーマシューティカルズ・インコーポレイテッド |
オピオイド鎮痛薬の調製および効用
|
WO2008026946A2
(en)
|
2006-08-30 |
2008-03-06 |
Genesis Research And Development Corporation Limited |
Compositions and methods for the treatment and prevention of neoplastic disorders
|
US20090074711A1
(en)
|
2006-09-07 |
2009-03-19 |
University Of Southhampton |
Human therapies using chimeric agonistic anti-human cd40 antibody
|
US20080221132A1
(en)
|
2006-09-11 |
2008-09-11 |
Xiong Cai |
Multi-Functional Small Molecules as Anti-Proliferative Agents
|
ATE502921T1
(de)
|
2006-10-19 |
2011-04-15 |
Auspex Pharmaceuticals Inc |
Substituierte indole
|
US9375440B2
(en)
|
2006-11-03 |
2016-06-28 |
Medtronic, Inc. |
Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
|
WO2008067378A2
(en)
|
2006-11-28 |
2008-06-05 |
Auspex Pharmaceuticals, Inc. |
Preparation and utility of substituted phenyltetrazoles
|
US20080146573A1
(en)
|
2006-12-04 |
2008-06-19 |
Auspex Pharmaceuticals, Inc. |
Preparation and utility of substituted oxzolidinones
|
US20080167312A1
(en)
|
2006-12-08 |
2008-07-10 |
Auspex Pharmaceuticals, Inc. |
Preparation and utility of substituted allylamines
|
BRPI0807046A2
(pt)
|
2007-02-09 |
2015-05-26 |
Tranzyme Pharma Inc |
Composto, composição farmacêutica, métodos de tratar um distúrbio, uma doença cardiovascular e um paciente que sofre de motilidade gastrointestinal reduzida ou disfuncional e, kit.
|
WO2008103899A1
(en)
|
2007-02-23 |
2008-08-28 |
Auspex Pharmaceuticals, Inc. |
Preparation and utility of non-nucleoside reverse transcriptase inhibitors
|
WO2008140859A1
(en)
|
2007-03-15 |
2008-11-20 |
Auspex Pharmaceuticals, Inc. |
Deuterated venlafaxines and 0-desmetylvenlafaxines with serotoninergic and / or norepinephrinergic activity
|
WO2008113100A1
(en)
*
|
2007-03-16 |
2008-09-25 |
Novogen Research Pty Ltd |
Method for inducing autophagy
|
JP2010523584A
(ja)
|
2007-04-02 |
2010-07-15 |
オースペックス・ファーマシューティカルズ・インコーポレイテッド |
置換ピリミジン
|
CA2683857A1
(en)
|
2007-04-10 |
2008-10-16 |
Auspex Pharmaceuticals, Inc. |
Substituted deuterium enriched thiophenes for the treatment of hypertension
|
US20080255200A1
(en)
|
2007-04-11 |
2008-10-16 |
Auspex Pharmaceuticals, Inc. |
Substituted benzimidazoles
|
US20080262086A1
(en)
|
2007-04-18 |
2008-10-23 |
Auspex Pharmaceuticals, Inc. |
Substituted anthranilic acids
|
BRPI0809843A2
(pt)
|
2007-04-26 |
2014-09-23 |
Auspex Pharmaceuticals Inc |
"composto, composição farmacêutica e uso de um composto"
|
US20080280886A1
(en)
|
2007-05-08 |
2008-11-13 |
Auspex Pharmaceuticals, Inc. |
Substituted ureas
|
WO2008141033A1
(en)
|
2007-05-08 |
2008-11-20 |
Auspex Pharmaceuticals Inc. |
Substituted naphthalenes
|
US20100216706A1
(en)
*
|
2007-05-15 |
2010-08-26 |
Horvath Tamas L |
Ghrelin Protects Substantia Nigra Dopamine Neurons
|
WO2008144602A1
(en)
|
2007-05-18 |
2008-11-27 |
Auspex Pharmaceuticals, Inc. |
Deuterated zamifenacin derivatives
|
EP2155889A4
(en)
|
2007-05-25 |
2010-06-16 |
Centocor Ortho Biotech Inc |
TOLL RECEPTOR 3 MODULATORS AND USES THEREOF
|
US7745665B2
(en)
|
2007-06-04 |
2010-06-29 |
Auspex Pharmaceuticals, Inc. |
Substituted phenethylamines
|
AU2008262291A1
(en)
|
2007-06-11 |
2008-12-18 |
Miikana Therapeutics, Inc. |
Substituted pyrazole compounds
|
CN101835761A
(zh)
|
2007-06-13 |
2010-09-15 |
奥斯拜客斯制药有限公司 |
取代的哌嗪
|
US8354223B2
(en)
*
|
2007-06-14 |
2013-01-15 |
Oncotherapy Science, Inc. |
Methods of identifying agents that modulate methylation of VEGFR1 by SMYD3
|
NZ599643A
(en)
|
2007-06-20 |
2013-11-29 |
Auspex Pharmaceuticals Inc |
Substituted N-aryl pyridinones as fibrotic inhibitors
|
WO2009006413A1
(en)
|
2007-06-30 |
2009-01-08 |
Auspex Pharmaceuticals, Inc. |
Substituted pyrrolidines
|
US20090011994A1
(en)
|
2007-07-06 |
2009-01-08 |
Bristol-Myers Squibb Company |
Non-basic melanin concentrating hormone receptor-1 antagonists and methods
|
CA2735167A1
(en)
|
2007-08-27 |
2009-03-05 |
Boston Biomedical, Inc. |
Composition of asymmetric rna duplex as microrna mimetic or inhibitor
|
WO2009032843A2
(en)
|
2007-09-06 |
2009-03-12 |
Auspex Pharmaceuticals, Inc. |
Deuterated ethambutols and their use
|
US20090088401A1
(en)
|
2007-09-27 |
2009-04-02 |
Andres Salazar |
In-situ cancer autovaccination with intratumoral stabilized dsRNA viral mimic
|